- Title
- Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials
- Creator
- Gao, L.; Zhao, F.-L.; Li, S-C.
- Relation
- Experimental and Clinical Endocrinology and Diabetes Vol. 120, Issue 6, p. 367-375
- Publisher Link
- http://dx.doi.org/10.1055/s-0032-1304619
- Publisher
- Johann Ambrosius Barth
- Resource Type
- journal article
- Date
- 2012
- Description
- Objectives: To date no consensus has been reached on whether to administer statin to patients with Polycystic Ovary Syndrome (PCOS) routinely. Therefore, we conduct a meta-analysis to synthesize the literatures regarding therapeutic effects of statins on PCOS. Methods: A comprehensive literature search was performed using terms such as polycystic ovary syndrome, ovary polycystic disease, PCOS, hyperandrogaenemia; simvastatin, atorvastatin, lipidemic-modulating drugs, lipid lowering drugs, and testosterone; randomized controlled trials in the following bibliographic databases: Medline, Embase, Cochrane Controlled Trials Register. Identified reference lists were checked manually. Results: In total, 4 RCTs were included. 3 of 4 studies were double-blinded while none reported whether of the data was analyzed using intention-to-treat analysis. Serum total testosterone and lipid profiles were included as investigation outcomes. Differences in reducing serum total testosterone were observed when comparing statin with placebo (Std MD= − 3.03, 95%CI − 5.85~ − 0.22, P=0.03) or statin + metformin with metformin (Std MD=− 1.07, 95%CI: − 2.06~ − 0.07, P=0.04). Heterogeneities were detected in both comparisons (I2=96% and 88% respectively). Meanwhile, statin was more effective than placebo in reducing LDL (WMD=− 0.87, 95%CI − 1.18~ − 0.55, P<0.0001), TC (WMD=− 1.23 95%CI − 1.35~ − 1.11, P<0.00001), TG (WMD= − 0.50, 95%CI − 0.73~ − 0.27, P<0.00001); and statin + metformin was more effective than metformin in lowering LDL (WMD= − 0.84, 95%CI: − 1.33~ − 0.354, P=0.0009), TC (WMD= − 1.28, 95%CI: − 1.47~ − 1.10, P<0.00001), and TG (WMD= − 0.27, 95%CI: − 0.36~ − 0.19, P<0.00001). Heterogeneities were detected during the meta-analysis.
- Subject
- Polycystic Ovary Syndrome (PCOS); hydroxymethylglutaryl-CoA reductase inhibitors; meta-analysis
- Identifier
- http://hdl.handle.net/1959.13/1311759
- Identifier
- uon:22272
- Identifier
- ISSN:0947-7349
- Language
- eng
- Reviewed
- Hits: 4261
- Visitors: 3207
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|